UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~August 2305, 2025

Boundless Bio, Inc.

(Exact Name of Registrant as Specified in Its Charter)


Delaware	001-41989	83-0751369
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10955 Alexandria Way, Suite 100,
San Diego, California		92121
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (858) 766-9912

    

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	BOLD	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.07.02 SubmissionResults of MattersOperations toand aFinancial Vote of Security HoldersCondition.

AtOn ~~the~~August ~~annual~~5, ~~meeting~~2025, ~~of stockholders of~~ Boundless Bio, Inc. (the Company) ~~held~~issued ona ~~June~~press ~~23,~~release ~~2025~~announcing ~~(the~~its ~~Meeting),~~financial ~~two~~results ~~proposals~~for ~~were~~the ~~voted~~quarter ~~upon~~ended byJune ~~the~~30, ~~Company’s stockholders~~2025. ~~The~~A ~~proposals~~copy ~~are~~of ~~described in detail in~~ the ~~Company’s~~press ~~definitive~~release ~~proxy~~is ~~statement~~attached ~~for~~hereto ~~the~~as ~~Meeting~~Exhibit ~~filed with the U~~99.S.1 ~~Securities~~ and ~~Exchange Commission on April 29, 2025. Below~~ is aincorporated ~~brief~~herein ~~description~~by ~~of, and the final results of the votes for, each proposal~~reference.

~~Proposal~~In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1:, ~~Each~~shall not be deemed “filed” for purposes of Section 18 of the ~~director~~Securities ~~nominees~~Exchange ~~was~~Act ~~elected~~of 1934, as aamended ~~Class~~(the IExchange ~~director~~Act), toor ~~hold~~otherwise ~~office~~subject ~~until~~to the ~~Company’s~~liabilities ~~2028~~of ~~annual~~that ~~meeting~~section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of ~~stockholders~~1933, ~~and~~as ~~until~~amended, ~~their~~or ~~respective~~the ~~successor~~Exchange isAct, ~~duly~~whether ~~elected~~made before or after the date hereof and ~~qualified,~~regardless of any general incorporation by reference language in any such filing, unless the ~~votes~~Company ~~set~~specifically ~~forth~~states ~~below~~in such filing that such information, or a portion thereof, is to be considered “filed” rather than furnished or incorporated by reference therein.

Nominee	Votes For		Votes Withheld		Broker Non‑Votes
Christine Brennan, Ph.D.		9,252,440		5,046,258		3,540,518
Nancy Whiting, Pharm.D.		9,758,214		4,540,484		3,540,518

Item 9.01 Financial Statements and Exhibits.

~~Proposal~~(d) 2: The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 by the votes set forth belowExhibits.

Votes For			Votes Against		Abstentions		Broker Non-Votes
ExhibitNumber		Description
	17,791,309			47,807		100		—
99.1		Press Release Issued on August 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BOUNDLESS BIO, INC.
Date:	~~June~~August 235, 2025	By:	/s/ Jessica Oien
			Name: Jessica OienTitle: Chief Legal Officer and Corporate Secretary

Filing Compare · Boundless Bio, Inc.